

## All Drugs/Drug Candidates Scored in Access Meter

Brand (generic)	Indication
Aimovig (erenumab)	Migraine
Ajovy (fremanezumab)	Migraine
Arikayce (amikacin liposome inhalation suspension)	Cystic fibrosis NTM
Azedra (iobenguane I-131)	NET
Bijuva (TX-001HR)	Menopause HRT
Biktarvy (bictegravir/emtricitabine/tenofovir)	HIV
Braftovi/Mektovi (binimetinib/encorafenib)	Melanoma (BRAF+)
Calquence (acalabrutinib)	CLL
CAM2038 (buprenorphine)	Opioid Use Disorder
Copiktra (duvelisib)	CLL, NHL
Delstrigo (doravine (DOR/3TC/TDF))	HIV/AIDS
Dsuvia (sufentanil)	Pain
Dupixent-asthma (dupilumab)	Eosinophilic asthma
Emgality (galcanezumab)	Migraine
Epidiolex (cannabidiol)	LGS and Dravet
Evenity (romosozumab)	Osteoporosis
fevipiprant	Asthma
Galafold (migalastat)	Fabry's disease
glasdegib	AML
Ilumya (tildrakizumab)	Psoriasis
Inbrija (levodopa)	Parkinson's
Jatenzo (testosterone undecanoate)	hypogonadism
larotrectinib	TRK+ cancers
Libtayo (cemiplimab)	SCC
Lorbrena (lorlatinib)	NSCLC
luspatercept	MDS, beta-thalassemia
Mavenclad (cladribine)	MS
Olinvo (oliceridine)	Acute pain
Olumiant (baricitinib)	RA
Onpattro (patisiran)	TTR amyloidosis
Orlissa (elagolix)	Endometriosis
ozanimod	MS
Palynziq (pegvaliase-pgpz)	Phenylketonuria
Pifeltro (doravirine)	HIV/AIDS
risankizumab	Psoriasis
sacituzumab govitecan	Breast cancer
samidorphan/buprenorphine (ALKS 5461)	MDD
selumetinib	Thyroid cancer
Sympazan PharmFilm (clobazam)	Lennox-Gastaut Syndrome
Takhzyro (lanadelumab)	HAE
Talzenna (talazoparib)	Breast cancer
Tbria (calcitonin-salmon)	Osteoporosis
Tegsedi (inotersen)	TTR amyloidosis
Tibsovo (ivosidenib)	AML (R/R, IDH1+)
Vizimpro (dacomitinib)	NSCLC
Waylivra (volanesorsen)	Familial chylomicronemia
Xyosted (testosterone enanthate)	Hypogonadism
Yupelri (revefenacin)	COPD
Zulresso (brexanolone)	Postpartum depression